Listen on the go
    • Faculty & Disclosures
    Prof. Paul Paik

    Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Prof. Paul Paik, MD, is a medical oncologist at the Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA, who specializes in the treatment of lung cancers. read more

    He is an associate attending physician at the Thoracic Oncology Service at MSKCC, an associate professor of medicine at Weill Cornell Medical College and serves as the clinical director for the Thoracic Oncology Program at MSKCC. Prof. Paik’s research focuses on squamous cell lung cancer, targeted therapeutics and translational therapies aimed at the metastatic process.

    Prof. Paul Paik discloses: Advisory board or panel fees from Bicara Therapeutics (relationship terminated), EMD Serono, Janssen Pharmaceuticals (relationship terminated), Mirati Therapeutics (relationship terminated) and Takeda (relationship terminated). Consultancy fees from Novartis (relationship terminated). Grants/research support from Bicara Therapeutics, EMD Serono and Genentech.
    Dr Yasushi Goto

    National Cancer Center Hospital, Tokyo, Japan

    Dr Yasushi Goto, MD, PhD, is the assistant chief in the Division of Thoracic Oncology at the National Cancer Center Hospital in Tokyo, Japan. He received his medical and doctorate degree from the University of Tokyo. read more

    Dr Goto’s current research focus is in medical oncology (thoracic malignancies) and translational medicine. He is an author on more than 50 scientific papers, including publications in the Journal of Thoracic Oncology, Journal of Clinical Oncology, The Lancet and New England Journal of Medicine. He is a member of steering committees for several global and domestic studies, and a primary investigator of the Japan Clinical Oncology Group trial. He is a member of the Japanese Society of Internal Medicine, the Japanese Respiratory Society, the Japanese Cancer Association, the Japan Lung Cancer Society, the Japanese Society of Medical Oncology, the American Society of Clinical Oncology, the European Society of Medical Oncology, and the International Association for the Study of Lung Cancer.

    Dr Yasushi Goto discloses: Consultancy fees from AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly, GSK, Guardant Health, Illumina, Janssen Pharmaceuticals, Kyorin Pharmaceutical, Merck, MSD, Novartis, Ono Pharmaceutical, Pfizer and Taiho Pharmaceutical. Grants/research support from Abbvie, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Guardant Health, Kyorin Pharmaceutical, MSD, Novartis, Ono Pharmaceutical, Pfizer and Preferred Network. Speakers’ bureau fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Guardant Health, Kyowa Kirin, Merck, MSD, Novartis, Ono Pharmaceutical, Pfizer, Taiho Pharmaceutical, Takeda, Thermo Fisher Scientific and Towa Pharmaceutical.
    Downloads

    View and download resources from this activity to support your learning and share with colleagues

    Part 1 Slides
    Part 1 Slides
    CORRECT!
    Next question
    touchONCOLOGY touchONCOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:

    • Lung Cancer

    An Introduction to Lung Cancer

    In some Western countries, the frequency and mortality of lung cancer are decreasing due to decades of public education and tobacco control policies, even though it still remains a major cause of mortality worldwide. Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.

    Lung Cancer Content

    Lung Cancer
    Watch Time: 18 mins
    touchIN CONVERSATION
    Personalized therapy for NSCLC: Biomarker testing, treatment and management in the presence of MET alterations
    CE/CME ACCREDITED Prof. Paul Paik, Dr Yasushi Goto Translations available:

    Two lung cancer specialists discuss the current recommendations for biomarker testing and the latest data on MET inhibitors for the management of patients with MET alterations.

    Learning objectives
    Learning Objectives
    • Outline the evolving landscape of biomarker testing in advanced NSCLC and the methods used to identify patients with MET alterations
    • Recall the latest efficacy and safety from MET-inhibitor clinical trials in advanced NSCLC and implications for management
    Lung Cancer, Immunotherapy
    Watch Time: 32 mins
    touchEXPERT OPINIONS
    Current and future considerations for the use of immune checkpoint inhibitors in non-small cell lung cancer
    CE/CME ACCREDITED Dr Pilar Garrido

    A leading expert discusses the current landscape and future perspectives of immune checkpoint inhibitors for the treatment of NSCLC

    Learning objectives
    Learning Objectives
    • Discuss the clinical implications for the latest data for immunotherapies in early-stage NSCLC
    • Evaluate the use of novel agents in combination with immunotherapy in NSCLC using the latest evidence
    • Describe how current and emerging biomarkers may guide immunotherapy treatment selection in NSCLC
    Lung Cancer
    Developed by Touch
    Sunil Singhal, AACR 2023: Intraoperative molecular imaging as a tool in cancer surgery
    Watch Time: 5 mins

    Intraoperative molecular imaging enables surgeons to utilise a cancer specific fluorescent dye to improve cancer removal. In this touchONCOLOGY interview, we speak with Dr Sunil Singhal (University of Pennsylvania, Philadelphia, PA, USA) to discuss intraoperative molecular imaging, with focus on its application in lung cancer. The presentation entitled ‘Intraoperative molecular imaging of lung cancer: The […]

    Lung Cancer
    Pafolacianine: A Diagnostic Agent to Identify Lung Cancer Lesions in Adults with Known or Suspected Lung Cancer
    Linda Martin

    touchREVIEWS in Oncology & Haematology. 2023;19(1):2-3 DOI: https://doi.org/10.17925/OHR.2023.19.1.2

    Accurately detecting lung tumours and their margins is important for disease outcomes.1,2 However, detection is challenging due to the use of minimally invasive surgery and current localization techniques, such as computed tomography (CT)-guided and endobronchial interventions, which add significantly to procedure time and risk of complications.3 Intraoperative imaging using a targeted agent to optically fluoresce cancerous cells may address these problems, in addition to locating […]

    Lung Cancer, Immunotherapy
    Watch Time: 48 mins
    touchMDT
    Uncharted territory: Introducing novel immunotherapeutic approaches for metastatic NSCLC without driver mutations
    CE/CME ACCREDITED Prof. Raffaele Califano, Prof. Lisa Holle, Prof. Albrecht Stenzinger and Mr Josh Colow Translations available:

    Leading specialists and a patient advocate discuss novel immunotherapies for non-driver mutation metastatic non-small cell lung cancer (NSCLC).

    Learning objectives
    Learning Objectives
    • Outline the determinants of response and resistance to immune checkpoint blockade in patients with non-driver mutation metastatic NSCLC
    • Discuss the mechanisms of action and latest data for novel immunotherapy regimens in the management of non-driver mutation metastatic NSCLC
    • Appraise strategies for involving patients with non-driver mutation metastatic NSCLC in their healthcare for optimal outcomes
    Lung Cancer
    Watch Time: 31 mins
    touchPANEL DISCUSSION
    Navigating the complexities of the NSCLC treatment pathway: A focus on antibody-drug conjugates
    Prof. Jarushka Naidoo, Dr Rebecca Heist, Dr Antonio Passaro Translations available:

    Experts in the management of lung cancer discuss emerging antibody-drug conjugates for the treatment of patients with non-small cell lung cancer (NSCLC)

    Learning objectives
    Learning Objectives
    • Outline the rationale for and mechanisms of action for antibody drug conjugates (ADCs) under investigation in NSCLC, and implications for patient selection
    • Evaluate the latest clinical trial data for ADCs in patients with advanced or metastatic NSCLC
    • Discuss incidence rates and severity of adverse events (AEs) associated with ADCs in metastatic NSCLC and potential role for therapeutic dose optimization strategies in AE management
    Lung Cancer
    Watch Time: 38 mins
    touchMDT
    Continuing the momentum in SCLC: Exploring second-line and novel therapy options
    CE/CME ACCREDITED Dr Barbara Melosky, Dr Sonia Amin Thomas, Dr Christine Argento, Dr Victoria Sherry

    MDT specialists discuss the current and emerging second-line treatment options for patients with extensive-stage small cell lung cancer (ES-SCLC)

    Learning objectives
    Learning Objectives
    • Describe the current and emerging second-line treatment options for patients with SCLC
    • Identify patient- and disease-related factors that affect treatment decisions for patients with SCLC in the second-line setting
    • Describe strategies to manage adverse events for patients with SCLC in the second-line treatment setting
    Lung Cancer
    Developed by Touch
    Gerard Zalcman, ESMO 2022: IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab in advanced non-small cell lung cancer
    Watch Time: 4 mins

    First-line immunotherapy is a standard treatment for patients with advanced non-small cell lung cancer. Prof. Gerard Zalcman (Bichat Hospital, Assistance Publique-Hôpitaux de Paris; Institute of Cancer AP-HP Nord, Paris, France) joins touchONCOLOGY to discuss the IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab, aiming to assess if 6-months nivolumab/ipilimumab duration was equivalent to continuation until progression […]

    Lung Cancer
    Developed by Touch
    Charles Swanton, ESMO 2022: Mechanism of action and an actionable inflammatory axis for air pollution may induce NSCLC in never-smokers
    Watch Time: 6 mins

    The mechanistic basis for non-small cell lung cancer (NSCLC) initiation in never smokers is unknown. The air pollutant, particulate matter, is known to be associated with the risk of NSCLC, however a direct cause and mechanism remains difficult to achieve. Prof. Charles Swanton (Francis Crick Institute, London, UK) joins touchONCOLOGY to discuss his study into […]

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72